

The landscape of kratom products has become increasingly complex with the emergence of concentrated 7-hydroxymitragynine (7-OH) products. These substances, often marketed as "7-OH," "7-Hydro," or even "legal morphine," represent a significant shift from traditional kratom products and carry substantially higher risks for addiction and serious health complications.
7-hydroxymitragynine, commonly referred to as 7-OH, is one of the naturally occurring compounds found in kratom leaves. However, while traditional kratom contains only trace amounts of 7-OH (typically less than 0.05% of the leaf), concentrated products now flood the market with dramatically higher concentrations.
These concentrated 7-OH products are not the same as traditional kratom. They are typically synthetic or semi-synthetic preparations that contain 7-OH levels that can exceed 40% purity. This concentration makes them 30-40 times more potent at opioid receptors than the primary kratom alkaloid, mitragynine, according to research published in medical journals.
The surge in concentrated 7-OH products has raised serious concerns among medical professionals and addiction specialists. Unlike traditional kratom, these products produce:
Rapid-Onset Effects
Higher Addiction Potential
Severe Withdrawal Symptoms
Many 7-OH products are deceptively labeled and marketed as "kratom extract" or "enhanced kratom." However, products containing more than 2% 7-OH are fundamentally different substances with opioid-like effects and risks. The Drug Enforcement Administration continues to monitor these substances as they evaluate their scheduling status. Some concerning marketing tactics include:
The FDA has issued warnings about specific 7-OH products after linking them to serious adverse events, including:
Recent independent lab testing has revealed that some products marketed as kratom actually contain extremely high concentrations of 7-OH, putting users at risk without their knowledge.
People who use concentrated 7-OH products often face more complex treatment needs than those using traditional kratom. Common challenges include:
Severe Physical Dependence Many individuals require the same evidence-based medications used for opioid use disorder, including buprenorphine (Suboxone, Sublocade) and naltrexone (Vivitrol). These treatments are supported by extensive research from the Substance Abuse and Mental Health Services Administration.
Intensive Withdrawal Management 7-OH withdrawal often mirrors prescription opioid withdrawal and may require medical supervision and support medications.
Higher Risk of Relapse The intense cravings associated with 7-OH use can make maintaining recovery more challenging without proper treatment support.